Published in J Bone Miner Res on February 01, 2008
How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int (2010) 1.68
Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int (2008) 1.61
Advanced CT bone imaging in osteoporosis. Rheumatology (Oxford) (2008) 1.58
Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int (2008) 1.39
High-resolution computed tomography for clinical imaging of bone microarchitecture. Clin Orthop Relat Res (2011) 1.32
Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol (2009) 1.30
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int (2010) 1.09
Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength. Rheumatology (Oxford) (2008) 1.08
Influence of remodeling on the mineralization of bone tissue. Osteoporos Int (2009) 1.07
In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos Int (2009) 1.07
Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int (2011) 1.03
A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). Osteoporos Int (2011) 1.02
Essential role of nuclear factor of activated T cells (NFAT)-mediated Wnt signaling in osteoblast differentiation induced by strontium ranelate. J Biol Chem (2010) 1.00
A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis (2013) 0.97
Anabolic agents and bone quality. Clin Orthop Relat Res (2011) 0.94
Possible benefits of strontium ranelate in complicated long bone fractures. Rheumatol Int (2010) 0.92
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal. Int J Womens Health (2010) 0.92
Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment. Springerplus (2014) 0.90
An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts. J Biol Chem (2011) 0.89
Strontium ranelate: in search for the mechanism of action. J Bone Miner Metab (2013) 0.87
Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials. Biomed Res Int (2014) 0.85
Goal-directed treatment of osteoporosis in Europe. Osteoporos Int (2014) 0.84
Blockade of receptor-activated G(i) signaling in osteoblasts in vivo leads to site-specific increases in cortical and cancellous bone formation. J Bone Miner Res (2011) 0.83
Effect of osteoporosis medications on fracture healing. Osteoporos Int (2015) 0.83
Histomorphometric interpretation of bone biopsies for the evaluation of osteoporosis treatment. Bonekey Rep (2012) 0.82
Microarchitecture in focus. Osteoporos Int (2010) 0.78
Healing of subtrochanteric atypical fractures after strontium ranelate treatment. Clin Cases Miner Bone Metab (2012) 0.78
Strontium doping of bone graft extender. Acta Orthop (2011) 0.78
From histology to micro-CT: Measuring and modeling resorption cavities and their relation to bone competence. World J Radiol (2014) 0.78
Bone quality and bone strength: benefits of the bone-forming approach. Clin Cases Miner Bone Metab (2014) 0.77
Mechanism of action of strontium ranelate: what are the facts? Clin Cases Miner Bone Metab (2010) 0.77
Development of new criteria for cortical bone histomorphometry in femoral neck: intra- and inter-observer reproducibility. J Bone Miner Metab (2014) 0.77
Treatment of osteoporosis: current state of the art. Wien Med Wochenschr (2014) 0.77
Strontium ranelate improves delayed healing of osteolytic lesions of the jaw in a man with chronic osteomyelitis. Case report. Clin Cases Miner Bone Metab (2014) 0.76
Localization of CaSR antagonists in CaSR-expressing medullary thyroid cancer. J Clin Endocrinol Metab (2013) 0.76
Strontium ranelate decreases the incidence of new caudal vertebral fractures in a growing mouse model with spontaneous fractures by improving bone microarchitecture. Osteoporos Int (2010) 0.76
Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis (2011) 0.76
Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group. Osteoporos Int (2016) 0.76
Bone: Strontium ranelate does not have an anabolic effect on bone. Nat Rev Endocrinol (2013) 0.76
Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture. Osteoporos Int (2010) 0.76
Trajectories of Bone Remodeling Markers and Bone Mineral Density during Treatment with Strontium Ranelate in Postmenopausal Women Previously Treated with Bisphosphonates. Clin Med Insights Endocrinol Diabetes (2014) 0.75
OSTEOPOROSIS DIAGNOSIS AND TREATMENT. Rev Bras Ortop (2015) 0.75
Normalization of bone mineral density after five years of treatment with strontium ranelate. Clin Cases Miner Bone Metab (2015) 0.75
Iliac crest histomorphometry and skeletal heterogeneity in men. Bone Rep (2016) 0.75
Osteoporosis drug effects on cortical and trabecular bone microstructure: a review of HR-pQCT analyses. Bonekey Rep (2016) 0.75
Structure Model Index Does Not Measure Rods and Plates in Trabecular Bone. Front Endocrinol (Lausanne) (2015) 0.75
Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis. Ther Adv Musculoskelet Dis (2010) 0.75
Imaging of diabetic bone. Endocrine (2017) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med (2006) 7.45
Estimates of optimal vitamin D status. Osteoporos Int (2005) 7.13
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am (2002) 5.95
Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (2013) 5.93
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab (2005) 5.31
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Global seabird response to forage fish depletion--one-third for the birds. Science (2011) 3.45
Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res (2010) 3.33
Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res (2008) 3.33
Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res (2007) 3.31
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Musculoskeletal ultrasound in rheumatology: a radiologic perspective. Arthritis Rheum (2005) 2.71
Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum (2002) 2.66
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res (2003) 2.38
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings. Radiology (2013) 2.22
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res (2007) 2.15
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis (2011) 2.13
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J Bone Miner Res (2006) 2.04
Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res (2007) 1.97
Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr (2004) 1.96
Biological markers in osteoarthritis. Nat Clin Pract Rheumatol (2007) 1.95
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest (2005) 1.88
Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. Gastroenterology (2011) 1.86
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res (2004) 1.76
What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res (2005) 1.76
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum (2008) 1.73
SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med (2002) 1.71
Bone marrow lesions in the knee are associated with increased local bone density. Arthritis Rheum (2005) 1.64
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res (2005) 1.57
Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res (2005) 1.56
Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med (2008) 1.54
Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. Ann Am Thorac Soc (2015) 1.54
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.54
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in postmenopausal women. Bone (2010) 1.52
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum (2008) 1.51
Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res (2012) 1.50
Severity of vertebral fractures is associated with alterations of cortical architecture in postmenopausal women. J Bone Miner Res (2009) 1.49
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone (2008) 1.48
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Estimated number of women likely to benefit from bone mineral density measurement in France. Joint Bone Spine (2004) 1.41
Value of the HLA-DRB1 shared epitope for predicting radiographic damage in rheumatoid arthritis depends on the individual patient risk profile. J Rheumatol (2006) 1.41
Measurement of breast density with dual X-ray absorptiometry: feasibility. Radiology (2002) 1.38
Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res (2004) 1.38
Associations of anatomical measures from MRI with radiographically defined knee osteoarthritis score, pain, and physical functioning. J Bone Joint Surg Am (2011) 1.37
Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem (2006) 1.36
Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol (2007) 1.33
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res (2008) 1.32
Contribution of trochanteric soft tissues to fall force estimates, the factor of risk, and prediction of hip fracture risk. J Bone Miner Res (2007) 1.29
Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in men. J Bone Miner Res (2011) 1.28
Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study. J Bone Miner Res (2005) 1.28
Knee osteoarthritis in obese women with cardiometabolic clustering. Arthritis Rheum (2009) 1.28
Advanced imaging assessment of bone quality. Ann N Y Acad Sci (2006) 1.26
Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. J Rheumatol (2003) 1.25
Accuracy of CT-based thickness measurement of thin structures: modeling of limited spatial resolution in all three dimensions. Med Phys (2003) 1.24
Clinical applications of body composition measurements using DXA. J Clin Densitom (2003) 1.23
Influence of blinding sequence of radiographs on the reproducibility and sensitivity to change of joint space width measurement in knee osteoarthritis. Arthritis Care Res (Hoboken) (2010) 1.23
Biomarkers in osteoarthritis. Curr Opin Rheumatol (2003) 1.22
Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res (2009) 1.22
Incidence and risk factors for vertebral fracture in women and men: 25-year follow-up results from the population-based Framingham study. J Bone Miner Res (2006) 1.21
Diagnosis of osteoporotic vertebral fractures: importance of recognition and description by radiologists. AJR Am J Roentgenol (2004) 1.20
Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res (2008) 1.19
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Brodie abscess: another type of chronic posttraumatic osteomyelitis. Eur Radiol (2003) 1.18
Recognizing and reporting osteoporotic vertebral fractures. Eur Spine J (2003) 1.18
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res (2003) 1.17
Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone (2005) 1.17
Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men--the MINOS study. J Bone Miner Res (2004) 1.16
Mineral maturity and crystallinity index are distinct characteristics of bone mineral. J Bone Miner Metab (2010) 1.16
Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab (2006) 1.16
Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Miner Res (2010) 1.16